Inhibition of melanoma growth by hemocyanin occurs via early apoptotic pathways

American Journal of Surgery

Volumn 190, Issue 5, 2005, Pages 713-716

  Somasundar, Ponnandai ^a   Riggs, Dale R ^a   Jackson, Barbara J ^a   McFadden, David W ^a  

^a WEST VIRGINIA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Apoptosis; Cell growth inhibition; Keyhole limpet hemocyanin; Melanoma

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; FLUORESCEIN ISOTHIOCYANATE; KEYHOLE LIMPET HEMOCYANIN; LIPOCORTIN 5;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CELL ASSAY; CELL DEATH; CELL GROWTH; CELL PROLIFERATION; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; HUMAN; HUMAN CELL; IN VITRO STUDY; MELANOMA; MELANOMA CELL; PRIORITY JOURNAL;

ANIMALS; APOPTOSIS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FLOW CYTOMETRY; HEMOCYANIN; HUMANS; MELANOMA; MOLLUSCA;

EID: 26844457171     PISSN: 00029610     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjsurg.2005.07.008     Document Type: Article

References (22)

1. A. Jemal, T. Murray, E. Ward Cancer statistics, 2005 CA Cancer J Clin 55 2005 259
2. S.T. McGillis, H. Fein Topical treatment strategies for non-melanoma skin cancer and precursor lesions Semin Cutan Med Surg 23 2004 174 183
3. A.M. Villa, B. Berman Immunomodulators for skin cancer J Drugs Dermatol 3 2004 533 539
4. J.R. Harris, J. Markl Keyhole limpet hemocyanin: molecular structure of a potent marine immunoactivator. A review Eur Urol 37 suppl 3 2000 24 33
5. A.O. Tzianabos Polysaccharide immunomodulators as therapeutic agents structural aspects and biologic function Clin Microbiol Rev 13 2000 523 533
6. C.A. Olsson, R. Chute, C.N. Rao Immunologic reduction of bladder cancer recurrence rate J Urol 111 1974 173 176
7. D.R. Riggs, W.F. Tarry, J.I. DeHaven Immunotherapy of murine transitional cell carcinoma of the bladder using alpha and gamma interferon in combination with other forms of immunotherapy J Urol 147 1992 212 214
8. C.D. Jurincic, U. Engelmann, J. Gasch, K.F. Klippel Immunotherapy in bladder cancer with keyhole-limpet hemocyanin a randomized study J Urol 139 1988 723 726
9. C.D. Jurincic-Winkler, K.A. Metz, J. Beuth, K.F. Klippel Keyhole limpet hemocyanin for carcinoma in situ of the bladder a long-term follow-up study Eur Urol 37 suppl 3 2000 45 49
10. D.L. Lamm, J.I. DeHaven, D.R. Riggs Keyhole limpet hemocyanin immunotherapy of bladder cancer laboratory and clinical studies Eur Urol 37 suppl 3 2000 41 44
11. D. Riggs, B. Jackson, L. Vona-Davis, D. McFadden In vitro anticancer effects of a novel immunostimulant keyhole limpet hemocyanin J Surg Res 108 2002 279 284
12. T. Mosmann Rapid colorimetric assay for cellular growth and survival application to proliferation and cytotoxicity assays J Immunol Methods 65 1983 55 63
13. th ed. 1983 McGraw-Hill New York
14. J. Ludbrook Multiple comparison procedures updated Clin Exp Pharmacol Physiol 25 1998 1032 1037
15. U. Veronesi, N. Cascinelli, J. Adamus Thin stage I primary cutaneous malignant melanoma. Comparison of excision with margins of 1 or 3 cm N Engl J Med 18 1988 1159 1162
16. J.D. Wagner, M.S. Gordon, T.Y. Chuang Current therapy of cutaneous melanoma Plast Reconstr Surg 105 2000 1774 1799 quiz 1800-1
17. J.M. Kirkwood, M.H. Strawderman, M.S. Ernstoff Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma the Eastern Cooperative Oncology Group Trial EST 1684 J Clin Oncol 14 1996 7 17
18. J.M. Kirkwood, J. Ibrahim, D.H. Lawson High-dose interferon alfa-2b does not diminish antibody response to GM2 vaccination in patients with resected melanoma results of the Multicenter Eastern Cooperative Oncology Group Phase II Trial E2696 J Clin Oncol 19 2001 1430 1436
19. M.B. Atkins, M.T. Lotze, J.P. Dutcher High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma analysis of 270 patients treated between 1985 and 1993 J Clin Oncol 17 1999 2105 2116
20. D.R. Riggs, B.J. Jackson, L. Vona-Davis A novel immunostimulant, keyhole limpet hemocyanin, inhibits human cancer growth and alters cytokine production in vitro Am J Surg 189 2005 680 684
21. D.W. McFadden, D.R. Riggs, B.J. Jackson, L. Vona-Davis Keyhole limpet hemocyanin, a novel immune stimulant with promising anticancer activity in Barrett's esophageal adenocarcinoma Am J Surg 186 2003 552 555
22. L. Vona-Davis, T. Vincent, S. Zulfigar Proteomic analysis of SEG-1 human Barrett's-associated esophageal adenocarcinoma cells treated with keyhole limpet hemocyanin J Gastrointest Surg 8 2004 1018 1023